Nautilus Biotechnology, a San Carlos, CA- and Seattle, WA-based company advancing a platform for analyzing and quantifying the human proteome, raised $76m in Series B funding.
The round was led by Vulcan Capital, with participation from Perceptive Advisors, Bezos Expeditions, and Defy Partners and previous investors AME Cloud Ventures, Andreessen Horowitz, Bolt, and Madrona Venture Group.
The company, which has raised $100m in total funding, intends to use the capital to accelerate development of its proprietary proteomics platform and the expansion of scientific and engineering staff across a variety of levels and disciplines.
Co-founded in 2016 by Sujal Patel, founder and CEO of Isilon Systems, Nautilus is a biotechnology company whose proteomics platform will analyze and quantify the human proteome by delivering single-molecule sensitivity, enabling acceleration of basic science research, improving the rate of therapeutic development, and speeding the adoption of personalized and predictive medicine.
FinSMEs
21/05/2020